| Combined relief of bloating, belching, and gas — BS50 | The combined weekly score for bloating, belching, and gas fell by at least 2 points in 47.4% of participants taking BS50 and 22.2% taking placebo (p=0.024). To qualify as a response, none of the three symptoms could worsen by 1 point or more. | 2/4 LowOne small six-week study that used subjective symptom ratings. The paper reports 38 participants assigned to each group, but the placebo response percentages are consistent with 36 participants. The paper does not explain why the number of observations differed in this analysis. | 11 publication describedThe probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial ↗ | 76 healthy adults aged 30–65 with mild bloating, belching, or gas, with 38 people per group. Everyone completed the study. | - The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial ↗
|
|---|
| Gas — BS50 | Gas decreased by at least 1 point in 47.4% of participants taking BS50 and 44.4% taking placebo. The study found no advantage for BS50 over placebo (p=0.80). | 2/4 LowOne small six-week study that used subjective symptom ratings. The paper reports 38 participants assigned to each group, but the placebo response percentages are consistent with 36 participants. The paper does not explain why the number of observations differed in this analysis. | 11 publication describedThe probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial ↗ | 76 healthy adults aged 30–65 with mild bloating, belching, or gas, with 38 people per group. Everyone completed the study. | - The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial ↗
|
|---|
| Bloating in the full group — MB40 | Bloating severity on a scale from 0 to 10 fell by 3.06 points with MB40 and 3.03 points with placebo. The difference between groups was not statistically significant. | 2/4 LowOne small four-week study. The main reported results cover 91 of the 100 participants assigned to groups. The study assessed several symptoms and considered different degrees of severity. | 11 publication describedA Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating ↗ | 100 adults aged 18–75 with pronounced or frequent bloating and no significant medical conditions. The per-protocol analysis included 91 people, 45 taking MB40 and 46 taking placebo. | - A Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating ↗
|
|---|
| Abdominal discomfort in the full group — MB40 | Abdominal discomfort on a scale from 0 to 10 fell by 2.34 points with MB40 and 2.77 points with placebo. The study found no advantage for MB40 over placebo. | 2/4 LowOne small four-week study. The main reported results cover 91 of the 100 participants assigned to groups. The study assessed several symptoms and considered different degrees of severity. | 11 publication describedA Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating ↗ | 100 adults aged 18–75 with pronounced or frequent bloating and no significant medical conditions. The per-protocol analysis included 91 people, 45 taking MB40 and 46 taking placebo. | - A Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating ↗
|
|---|
| Gas in the full group — MB40 | Gas severity on a scale from 0 to 10 fell by 2.24 points with MB40 and 2.12 points with placebo. The difference between groups was not statistically significant. | 2/4 LowOne small four-week study. The main reported results cover 91 of the 100 participants assigned to groups. The study assessed several symptoms and considered different degrees of severity. | 11 publication describedA Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating ↗ | 100 adults aged 18–75 with pronounced or frequent bloating and no significant medical conditions. The per-protocol analysis included 91 people, 45 taking MB40 and 46 taking placebo. | - A Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating ↗
|
|---|
| Bloating in the subgroup of men — MB40 | Among men, bloating severity fell by 3.71 points with MB40 and 2.33 points with placebo on a scale from 0 to 10. The numerical difference favored the supplement, but it was not statistically significant. | 1/4 Very lowA very small subgroup of 11 and 10 men. The paper says the analysis by sex was planned. The published trial registration does not independently confirm this. The result for the full group was null. The numerical differences among men did not reach statistical significance, and the study tested several symptoms. | 11 publication describedA Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating ↗ | The subgroup included 21 men who completed the protocol, 11 taking MB40 and 10 taking placebo. The full study included 100 adults aged 18–75 with pronounced or frequent bloating. | - A Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating ↗
|
|---|
| Days with abdominal discomfort in the subgroup of men — MB40 | Among men, the number of days per week with abdominal discomfort fell by 1.82 with MB40 and 0.50 with placebo. The difference in change was 1.32 days. The study found no statistically significant advantage over placebo. | 1/4 Very lowA very small subgroup of 11 and 10 men. The paper says the analysis by sex was planned. The published trial registration does not independently confirm this. The result for the full group was null. The numerical differences among men did not reach statistical significance, and the study tested several symptoms. | 11 publication describedA Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating ↗ | The subgroup included 21 men who completed the protocol, 11 taking MB40 and 10 taking placebo. The full study included 100 adults aged 18–75 with pronounced or frequent bloating. | - A Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating ↗
|
|---|
| Days with gas in the subgroup of men — MB40 | Among men, the number of days per week with gas fell by 1.41 with MB40 and 0.35 with placebo. The difference in change was 1.06 days. The study found no statistically significant advantage over placebo. | 1/4 Very lowA very small subgroup of 11 and 10 men. The paper says the analysis by sex was planned. The published trial registration does not independently confirm this. The result for the full group was null. The numerical differences among men did not reach statistical significance, and the study tested several symptoms. | 11 publication describedA Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating ↗ | The subgroup included 21 men who completed the protocol, 11 taking MB40 and 10 taking placebo. The full study included 100 adults aged 18–75 with pronounced or frequent bloating. | - A Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating ↗
|
|---|
| General well-being — R0179 | The study found no improvement in general well-being. Average scores for six symptom categories on a daily questionnaire stayed below 1 point on a scale from 0 to 6. Symptoms were mild at baseline. | 2/4 LowThe groups were small, with about 20 people each, and the study primarily assessed tolerability. Symptoms were mild at baseline, limiting the study's ability to detect improvement. | 11 publication describedEvaluation of Bacillus subtilis R0179 on gastrointestinal viability and general wellness: a randomised, double-blind, placebo-controlled trial in healthy adults ↗ | 83 healthy adults aged 18–50 were assigned to four groups. A total of 81 completed the study, including 21 at the 0.1 billion CFU dose and 20 each at the 1 billion CFU dose, the 10 billion CFU dose, and placebo. | - Evaluation of Bacillus subtilis R0179 on gastrointestinal viability and general wellness: a randomised, double-blind, placebo-controlled trial in healthy adults ↗
|
|---|
| Digestive symptoms — R0179 | Digestive symptoms did not improve on the GSRS questionnaire. Average scores for individual symptom categories ranged from 1.1 to 1.9 on a scale from 1 to 7, where 1 means no discomfort. | 2/4 LowThe groups were small, with about 20 people each, and the study primarily assessed tolerability. Symptoms were mild at baseline, limiting the study's ability to detect improvement. | 11 publication describedEvaluation of Bacillus subtilis R0179 on gastrointestinal viability and general wellness: a randomised, double-blind, placebo-controlled trial in healthy adults ↗ | 83 healthy adults aged 18–50 were assigned to four groups. A total of 81 completed the study, including 21 at the 0.1 billion CFU dose and 20 each at the 1 billion CFU dose, the 10 billion CFU dose, and placebo. | - Evaluation of Bacillus subtilis R0179 on gastrointestinal viability and general wellness: a randomised, double-blind, placebo-controlled trial in healthy adults ↗
|
|---|
| Bowel movement frequency — BS50 | Bowel movement frequency did not increase more with BS50 than with placebo. At baseline, the groups averaged 8.6 and 7.9 bowel movements per week, respectively. At week six, they averaged 9.4 and 9.3. The comparison of changes at week six yielded p=0.42. | 2/4 LowOne small six-week study in which participants kept a bowel movement diary. On average, participants had regular bowel movements and normal stool consistency before the course began. Chronic constipation was not required for participation. | 11 publication describedThe probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial ↗ | 76 healthy adults aged 30–65 with mild bloating, belching, or gas, with 38 people per group. Everyone completed the study. | - The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial ↗
|
|---|
| Stool consistency — BS50 | Stool consistency did not change more with BS50 than with placebo. The mean Bristol Stool Scale score went from 3.9 to 3.8 with BS50 and from 3.6 to 3.7 with placebo. The overall analysis of changes yielded p=0.29. | 2/4 LowOne small six-week study in which participants kept a bowel movement diary. On average, participants had regular bowel movements and normal stool consistency before the course began. Chronic constipation was not required for participation. | 11 publication describedThe probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial ↗ | 76 healthy adults aged 30–65 with mild bloating, belching, or gas, with 38 people per group. Everyone completed the study. | - The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial ↗
|
|---|
| Constipation symptoms — heat-treated BG01-4 | In the main analysis, the authors reported a 33% reduction in constipation symptoms with BG01-4 and a 15% reduction with placebo, as measured by a questionnaire. | 1/4 Very lowOne preliminary study in which 13 of the 80 participants assigned to groups did not complete the protocol. The main figure and the table for the additional analysis show different amounts of improvement in constipation. The text also contains errors in group sizes. These discrepancies account for the very low confidence. | 11 publication describedBacillus Subtilis (BG01-4(TM)) Improves Self-Reported Symptoms for Constipation, Indigestion, and Dyspepsia: A Phase 1/2A Randomized Controlled Trial ↗ | Adults aged 18–75 with self-reported long-standing intestinal complaints. People with irritable bowel syndrome (IBS) were excluded. The study flow diagram shows 80 people assigned to groups (42 and 38) and 67 included in the analysis (34 and 33). | - Bacillus Subtilis (BG01-4(TM)) Improves Self-Reported Symptoms for Constipation, Indigestion, and Dyspepsia: A Phase 1/2A Randomized Controlled Trial ↗
|
|---|
| Days with cold-like symptoms — CU1 | Over 16 weeks, participants reported cold-like symptoms on an average of 4.4 days with CU1 and 6.2 days with placebo. The difference was not statistically significant (p=0.1027). | 2/4 LowOne study of 100 participants over one winter. The study looked at respiratory symptoms in a separate, additional analysis. The primary outcome combined respiratory and intestinal infections. | 11 publication describedProbiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study ↗ | 100 independently living adults aged 60–74 with no severe chronic conditions who reported at least two episodes of infection the previous winter, with 50 participants per group. Everyone completed the study. | - Probiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study ↗
|
|---|
| Participants with a cold-like episode — CU1 | At least one respiratory episode occurred in 24 of 50 participants taking CU1 (48%) and 31 of 50 taking placebo (62%). The difference was not statistically significant (p=0.1609). | 2/4 LowOne study of 100 participants over one winter. The study looked at respiratory symptoms in a separate, additional analysis. The primary outcome combined respiratory and intestinal infections. | 11 publication describedProbiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study ↗ | 100 independently living adults aged 60–74 with no severe chronic conditions who reported at least two episodes of infection the previous winter, with 50 participants per group. Everyone completed the study. | - Probiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study ↗
|
|---|
| Days with symptoms of respiratory or intestinal infection — CU1 | Over 16 weeks, participants averaged 5.1 days with symptoms of respiratory or intestinal infection with CU1 and 6.6 days with placebo. The difference was not statistically significant (p=0.2015). | 2/4 LowOne study of 100 participants over one winter. This was the primary outcome for the full study population and included both respiratory and intestinal infections. | 11 publication describedProbiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study ↗ | 100 independently living adults aged 60–74 with no severe chronic conditions who reported at least two episodes of infection the previous winter, with 50 participants per group. Everyone completed the study. | - Probiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study ↗
|
|---|
| Self-rated sleep quality — BS50 | Self-rated sleep quality did not change. At baseline, the average rating was about 7 out of 10, indicating good sleep. The authors did not publish separate figures showing how each group rated its sleep after the course. | 2/4 LowOne small six-week study that assessed sleep by self-report. Most participants were already sleeping well before dosing began. The authors reported a null result without giving final figures for each group. | 11 publication describedThe probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial ↗ | 76 healthy adults aged 30–65 with mild bloating, belching, or gas, with 38 people per group. Everyone completed the study. | - The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial ↗
|
|---|
| Proportion of participants with good or excellent sleep — BS50 | The proportion of participants who rated their sleep as good or excellent did not change. More than 75% gave these ratings before the course began. The exact proportions for each group after the course were not published. | 2/4 LowOne small six-week study that assessed sleep by self-report. Most participants were already sleeping well before dosing began. The authors reported a null result without giving final figures for each group. | 11 publication describedThe probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial ↗ | 76 healthy adults aged 30–65 with mild bloating, belching, or gas, with 38 people per group. Everyone completed the study. | - The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial ↗
|
|---|